Therapy-related myelodysplastic syndrome with trisomy 1q due to der(1;7) and megakaryoblastic proliferation developing during complete remission of therapy-related acute myeloid leukemia with t(8;21).
Therapy-related acute myeloid leukemia (t-AML) with t(8;21) and therapy-related myelodysplastic syndrome (t-MDS) with trisomy 1q due to der(1;7) developed in the same patient with T-cell lymphoma at intervals of six years. After the development of t-MDS with trisomy 1q, during complete remission of t-AML, the number of megakaryoblasts increased to maximally 74% of leukocytes in the blood. This is a very rare case of two separate therapy-related myeloid malignancies (early t-AML and late t-MDS) and is also a notable case of t-MDS with trisomy 1q due to der(1;7) accompanied by megakaryoblastic proliferation.
Sakai
Chikara
C
Division of Hematology-Oncology, Chiba Cancer Center Hospital, Chiba.
Matsubayashi
Keiko
K
Saotome
Takashi
T
Ishii
Akihiro
A
Kumagai
Kyoya
K
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001707:Biopsy, Needle; D002869:Chromosome Aberrations; D002878:Chromosomes, Human, Pair 1; D018450:Disease Progression; D004198:Disease Susceptibility; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D018570:Risk Assessment; D014314:Trisomy / Q000175:diagnosis / Q000235:genetics*